tbuckley/cabot-search huggingface dataset:
Abstract P5-10-17: Evaluation of PgR status by immunohistochemistry may be inferior to PgR results by Oncotype DX for assessing the recurrence risk in ER+/HER2- breast cancer with low or intermediate tumor proliferation
Authors: Peter Sinn, Mark Kriegsmann, Ute Felten, Jürgen Wacker, Andreas Schneeweiss, Zsuzsanna Varga
Journal: Cancer Research (2015)

Abstract Background: Loss of progesterone receptor expression is known to be a predictor of Luminal-B subtype, and is of independent prognostic significance in luminal type breast cancer. However, the threshold of PgR status in IHC has been subject to debate, and the PgR status as reported by IHC not infrequently is at variance with the PgR result as reported by the Oncotype DX (ODX) assay. Methods: We retrospectively reviewed tumor IHC and ODX data from resection specimens with ER+/HER2- breast cancer, and low to intermediate Ki-67 proliferation rates (Ki-67 &amp;lt; 30%). A total of 74 specimens were re-analyzed, all from resection specimens that had been selected for ODX assay for the purpose of planning of adjuvant chemotherapy, from two institutions (Univ. Heidelberg, Germany, and Univ. Zurich, Switzerland). PgR expression of &amp;lt; 10% using IHC (clone PgR636, Ventana and Dako systems) or PgR values of &amp;lt; 5,5 in ODX assay were considered negative. Results: All cases were positive for ER by IHC and ODX, and 20% were negative for PgR by ODX assay. This compared to only 8% of negativity by IHC, but all except one case negative for PgR by IHC were also correctly identified as PgR negative by ODX. Median ODX recurrence score (RS) was 35 for PgR negativity by ODX assay, as compared to 30 for negative PgR status by IHC. For positive PgR status, median RS was calculated as 15 vs. 17 by ODX vs. IHC. Risk categories by ODX were high (RS &amp;gt;= 31) in 9 cases with negative PgR status by ODX, but only 3 of these high risk cases were negative for PgR by IHC. Median Ki-67 values were 22.5 for PgR negative cases by ODX as compared to 15 for PgR negative cases by IHC. Similar results were obtained when a higher PgR threshold of 20% was applied to IHC results. Conclusions: In luminal type breast cancers, the evaluation of PgR status by IHC may underestimate the proportion of PgR negative cases and did not identify most cases of tumors with a high risk of recurrence. This may be caused by an overly high sensitivity of PgR status in routine automated immunohistochemistry. Citation Format: Peter Sinn, Mark Kriegsmann, Ute Felten, Jürgen Wacker, Andreas Schneeweiss, Zsuzsanna Varga. Evaluation of PgR status by immunohistochemistry may be inferior to PgR results by Oncotype DX for assessing the recurrence risk in ER+/HER2- breast cancer with low or intermediate tumor proliferation [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-10-17.
MEDICO-DENTAL RELATIONS; THE DENTIST'S VIEWPOINT
Authors: J. T. O'rourke
Journal: Annals of Internal Medicine (1936)

Article1 August 1936MEDICO-DENTAL RELATIONS; THE DENTIST'S VIEWPOINTJ. T. O'ROURKE, B.S., D.D.S., F.C.A.D.J. T. O'ROURKE, B.S., D.D.S., F.C.A.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-2-233 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe question of medico-dental relations is one which has been discussed for many years. It was originally prompted by the empirical findings of those early practitioners who had observed either a favorable response to the elimination of certain oral conditions, or the damaging effects of faulty dental technology. The case reports of Benjamin Rush and his contemporaries on the benefits frequently accompanying the elimination of oral infections are well known. The period in which these early practitioners lived did not offer such opportunities for investigation as exist today, yet their frequent reports on medico-dental relations are not without value.The...References1. HARRIS CA: Principles and practice of dental surgery, 3rd Ed., 1848, page 38. Google Scholar2. HARTZELLHENRICI TBAT: Microscopic study of pulp from infected teeth, Jr. Dent. Res., 1920, ii, 537-550. Google Scholar3. MCNEVINVAUGHAN : Mouth infections and their relation to systemic disease, vol. 1, page 78, Joseph Purcell Research Memorial, New York. Google Scholar4. HARTZELLHENRICI TBAT: The bacteriology of vital pulps, Jr. Dent. Res., 1919, i, 421. Google Scholar5. THOMA KH: Infected vital dental pulp, Jr. Dent. Res., 1928, viii, 529-550. CrossrefGoogle Scholar6. HADEN RL: Dental infections and systemic disease, 2nd Ed., 1936, Lea and Febiger, Philadelphia, page 160. Google Scholar7. PEMBERTON R: Arthritis and rheumatoid conditions, 2nd Ed., 1935, Lea and Febiger, Philadelphia, page 166. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Louisville, Kentucky*Presented at the Detroit meeting of the American College of Physicians, March 3, 1936. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRelationship Between Dental and Cardiovascular Disease 1 August 1936Volume 10, Issue 2Page: 233-240 ePublished: 1 December 2008 Issue Published: 1 August 1936 PDF downloadLoading ...
Abstract 919: BIM as a predictive biomarker for VEGFR inhibitor in metastatic renal cell carcinoma
Authors: Jee Hung Kim, Hoi Young Lee, Woo Sun Kwon, Kyu Hyun Park, Ho-yeong Lim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha
Journal: Cancer Research (2014)

Abstract Angiogenesis is an important target for metastatic renal cell carcinoma(mRCC), resulting in several VEGFR tyrosine-kinase inhibitors(TKIs)in clinical practice. Approximately 35% of mRCC patients do not get the benefit from TKIs treatment, including sunitinib, sorafenib or the other VEGF pathway blockers, due to resistance and/or drug induced toxicities. Despite these initial insights, no validated biomarkers that identify which mRCC patients benefit most from antiangiogenic therapy have been discovered. Pro-apoptotic Bcl-2 family member (BIM) is a particularly critical mediator of targeted therapy-induced apoptosis in solid tumors. BIM upregulation is required for TKI to induce apoptosis in tyrosine kinase driven cancer. According to recent several studies, BIM deletion polymorphism was identified as one of the primary resistant mechanisms of various TKIs in EGFR mutated NSCLC or CML. However, there has been no study that confirms germline BIM deletion could confer the resistance to several VEGFR TKIs in treatment with mRCC. Here, we evaluated the possibility of germline and tumor tissue BIM deletion as a potential biomarker for VEGFR TKI resistance in mRCC. BIM deletion polymorphism status of gDNA from 55 formalin fixed paraffin embedded(FFPE) tumor tissues and 98 peripheral blood mononucleated cells (PBMC) of mRCC patients was determined by separated PCR. BIM protein expression level was evaluated by immunohistochemistry. Among these samples, 19 samples overlapped FFPE and PBMC and these sample results were exactly the same comparing either wild type or deletion. BIM deletion(heterozygous) accounted for 18.2% of the 121 total mRCC patients.We observed these patients with BIM deletion showed poor prognosis with TKIs treatments (response rate of treatment with sunitinib in BIM wild group and BIM deletion group : 24.6% versus 16.7%). Our study identified BIM a possible genetic biomarker that can predict the efficacy to VEGFR TKIs treatment in mRCC patients. Especially, as germline BIM deletion in the PBMC showed the concurrdence with tissue polymorphysim, it might be feasible to predict the response to antiangiogenic agent therapy simply through simple blood sampling. In conclusion, BIM deletion polymorphism might be a useful candidate marker for selecting mRCC patients for TKIs treatment. Citation Format: Jee Hung Kim, Hoi Young Lee, Woo Sun Kwon, Kyu Hyun Park, Ho-yeong Lim, Joong Bae Ahn, Hyun Cheol Chung, Sun Young Rha. BIM as a predictive biomarker for VEGFR inhibitor in metastatic renal cell carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 919. doi:10.1158/1538-7445.AM2014-919
401. Engineering Retroviral Vectors for Stem Cell Therapies - Overcoming the Effect of Gene Silencing
Authors: Gary K. Lee, David V. Schaffer
Journal: Molecular Therapy (2004)

The combined application of gene therapy and stem cell engineering for tissue regeneration have has drawn immense recent interest. In recent clinical trials with several patients who suffered from different forms of severe combined immunodeficiency syndrome (SCID), corrective genes were introduced into the patients' hematopoeitic stem cells via Moloney Murine Leukemia (MoMLV) viral vectors. This marked the first successful reports of gene therapy clinical trials. However, improvements to the vectors are needed to improve gene expression and safety of retroviral gene delivery to stem cells. For example, MoMLV vectors suffer from transcriptional silencing in many stem cell systems in vitro and in vivo, and enhancing gene expression after vector delivery could improve therapeutic efficacy, as well as improve safety by lowering the necessary dosage. The mechanism by which stem cells shutdown expression from an integrated retrovirus is not completely understood, but it is thought to be achieved via a combination of DNA methylation, histone modification, and chromatin remodeling. So far, five different regions within the retroviral genome have been identified as recognized targets that promote silencing, most of which lie within the U3 region of the viral Long Terminal Repeat (LTR). The effect of silencing can be reduced by modification and/or deletions of these regions; however, complete relief has never been achieved. Furthemore, improvements in long-term expression by these LTR modifications usually come at the cost of significant reductions in viral titer.
Abstract 11302: Sevoflurane Pre-Conditioning Effectively Ameliorates Diabetic Myocardial Ischemia/Reperfusion Injury via Differential Regulation of p38 and ERK
Authors: Jianli Zhao, Jingjing Li, Rui Li, Liyuan Jiao, Yanqing Zhang, Lili Wang, Yuexing Yuan, Wayne Bond Lau, Xin Ma, Yajing Wang
Journal: Circulation (2014)

Diabetes (DB) significantly exacerbates myocardial ischemia/reperfusion (MI/R) injury. Unfortunately, conventional pre-conditioning (PreCon) provides diminished cardioprotection during DB, due partially to impaired AMP-activated protein kinase (AMPK) signaling. The current study investigated whether PreCon by inhaled anesthetic sevoflurane (SF-PreCon) remains protective in DB, and if so, to dissect the involved mechanisms. Non-diabetic (ND) or high-fat diet-induced DB mice were subjected to MI/R and randomized into control and SF-PreCon (3 cycles of 15 minute-exposures to 2% sevoflurane prior to MI) groups. As expected, SF-PreCon significantly reduced MI/R injury in ND mice. Importantly, SF-PreCon also significantly reduced MI/R injury in DB mice, as evidenced by reduced apoptosis (-23.1±1.6, P&lt;0.01), decreased infarct size (-21.2±2.3%, P&lt;0.01), and augmented cardiac function (+24±3.0%, P&lt;0.01). To determine the role of AMPK in SF-PreCon-mediated cardioprotection, the effect of SF-PreCon upon MI/R injury was determined in cardiac specific AMPKα2 dominant negative overexpression mice (AMPK-DN). We demonstrate SF-PreCon remained cardioprotective in AMPK-DN mice. To explore the responsible molecular mechanisms, multiple cell-survival signaling molecules were screened. Interestingly, SF-PreCon differentially regulated mitogen-activated protein kinase (MAPK) family members in the MI/R heart. In ND mice, SF-PreCon dramatically reduced (-81±7.2%) MI/R-induced activation of p38, a pro-death MAPK, without significantly altering ERK and JNK. In DB and AMPK-DN mice, the inhibitory effect of SF-PreCon upon p38 activation was significantly blunted (DB: -8±2.1%) or virtually abolished (AMPK-DN). However, SF-PreCon significantly increased (P&lt;0.05) phosphorylation of ERK1/2, a pro-survival MAPK. Collectively, we demonstrate SF-PreCon protected the heart via AMPK-dependent inhibition of pro-death MAPK in ND mice. However, SF-PreCon exerts its cardioprotective actions via AMPK-independent activation of pro-survival MAPK in DB mice. These results suggest SF-PreCon may be a superior intervention over conventional PreCon in DB patients, where AMPK signaling is impaired.
Characterization of dendritic cell differentiation pathways from cord blood CD34+CD7+CD45RA+hematopoietic progenitor cells
Authors: Bruno Canque, Sandrine Camus, Ali Dalloul, Edmond Kahn, Micaël Yagello, Colette Dezutter-Dambuyant, Daniel Schmitt, Christian Schmitt, Jean Claude Gluckman
Journal: Blood (2000)
Interventions for Hypochondriasis in Primary Care—Reply
Authors: Arthur J. Barsky, David K. Ahern
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2684: Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody
Authors: Enza Piccolo, Sara Trani, Nicola Tinari, Cosmo Rossi, Rossana L. Sorda, Rossano Lattanzio, Maurizia D'Egidio, Annalisa D. Risio, Antonino Grassadonia, Francesca Spinella, Anna Bagnato, Mauro Piantelli, Clara Natoli, Stefano Iacobelli
Journal: Cancer Research (2014)

Abstract Background: Accumulating evidence indicates that serum and tissue levels of the lectin galactoside-binding soluble 3 binding protein (LGALS3BP), a secreted glycoprotein, are elevated in human cancer. Recently, we have identified LGALS3BP as a factor capable of stimulating angiogenesis of microvascular endothelial cells in culture as well as in vivo. However, the potential therapeutic implications of LGALS3BP function blockade, has not been explored yet. Methods: Here we tested the ability of an anti-LGALS3BP monoclonal antibody, named SP-2, to antagonize LGALS3BP-induced angiogenesis and tumor growth. Results: SP-2 dose-dependently inhibited HUVEC tubulogenesis induced by either conditioned medium of breast cancer and melanoma cells or purified recombinant LGALS3BP. This was accompanied by inhibition of FAK, Akt and ERKs phosphorylation as well as FAK recruitment to membrane sites and actin remodeling. In vivo, SP-2 inhibited LGALS3BP-stimulated angiogenesis and restrained growth of different xenograft models of human cancer. Finally, the combination of SP-2 with low-dose Bevacizumab was more effective than either agent alone in suppressing angiogenesis and tumor growth. Conclusions: Targeting LGALS3BP with SP-2 could represent a promising therapeutic approach for LGALS3BP expressing tumors. Citation Format: Enza Piccolo, Sara Trani, Nicola Tinari, Cosmo Rossi, Rossana La Sorda, Rossano Lattanzio, Maurizia D'Egidio, Annalisa Di Risio, Antonino Grassadonia, Francesca Spinella, Anna Bagnato, Mauro Piantelli, Clara Natoli, Stefano Iacobelli. Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2684. doi:10.1158/1538-7445.AM2014-2684
Abstract 13993: Impact of Prasugrel Pretreatment and Timing of Coronary Artery Bypass Grafting on Clinical Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction: From the Accoast Study
Authors: Dariusz Dudek, Petr Widimsky, Leonardo Bolognese, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, LeRoy LeNarz, Debra L Miller, Eileen Brown, Jurrien M ten Berg, Gilles Montalescot
Journal: Circulation (2014)

Objectives: We evaluated the impact of prasugrel pretreatment and timing of coronary artery bypass grafting (CABG) on clinical outcomes of patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing CABG based on data from ACCOAST. Methods: We evaluated the impact of troponin, prasugrel pretreatment and CABG timing on clinical outcomes of NSTEMI patients undergoing CABG through 30 days from ACCOAST. Results: CABG patients versus PCI or medically managed patients were more often male, diabetic, had peripheral arterial disease and a higher GRACE score. By randomization assignment, 157 patients received a 30-mg loading-dose of prasugrel before CABG; 157 patients did not. CABG patients were grouped by tertiles of time from randomization to CABG; baseline characteristics in the Table. Patients in the lowest tertile had significantly more events (cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa bailout) and all TIMI major bleeds than those in the other 2 groups (p&lt;0.045, p&lt;0.002 respectively), but the patients in the higher 2 groups were not significantly different from each other. No difference was detected in all cause death among the 3 groups (p&gt;0.39). A multivariate model evaluated 5 possible predictors of the composite endpoint of all cause death, MI, stroke and TIMI major bleeding. Time from randomization to CABG (HR 0.84 for each 1 hour of delay), left main disease presence (HR 1.76), and region of enrollment (Eastern Europe vs other, HR 3.83) were significant predictors but not prasugrel pretreatment or baseline troponin level ≥3xULN. Conclusions: In this group of high-risk patients presenting with NSTEMI, early surgical revascularization carried an increased risk of bleeding and ischemic complications, without impact on all-cause mortality. No impact of baseline troponin or prasugrel pretreatment (important factors influencing time of CABG) on clinical outcomes was confirmed.
Exercise in Health and Disease: Evaluation and Prescription for Prevention and Rehabilitation.
Authors: Michael L. Pollock, Jack H. Wilmore
Journal: Annals of Internal Medicine (1985)

Part 1 Physical Activity in Health and Disease: Cardiovascular Disease: Obesity and Weight Control. Part 2 Physiology of Exercise Related to Fitness Development and Maintenance: Cardiorespiratory Function: Body Composition Alterations with Exercise: Musculoskeletal Function. Part 3 Prescription for Programs of Prevention and Rehabilitation: Medical Screening and Evaluation Procedures: Prescribing Exercise for the Apparently Healthy: Prescribing Exercise for Rehabilitation of the Cardiac Patient: Special Consideration in Prescribing Exercise. Appendices: Appendix A. Medical Screening and Exercise: Appendix B. Additional Information and Forms Used in Cardiac Rehabilitation Programs: Appendix C. Prevention of Heat Injuries During Distance Running.
Histocompatibility Genes of the Mouse. II. Production and Analysis of Isogenic Resistant Lines&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Snell Gd, Jackson Rb
Journal: JNCI Journal of the National Cancer Institute (1958)

The production and H-gene typing of isogenic resistant (IR) lines in the mouse is described. Thirty-eight lines reached a stage of development where significant information as to their genotype could be obtained; 26 of these were studied in some detail. Of the 38 original IR lines, 30 were shown to be distinguished from their inbred or “coisogenic” mate by a difference at the H-2 locus. One coisogenic pair, C3H and C3H.K, differs at H-1, another, C57BL/10 and B10.LP, at H-3. Of the 6 remaining lines, 1 probably had an H-1 difference, 3 were uncertain, and 2, still under test, may serve to define new loci. Two lines served to identify new H-2 alleles: D1.C is H-2c AKR.M is H-2m. The component test showed D1.C to have the D component, and AKR.M the K component. Linkage tests showed 7.1 ± 4.5 percent crossing over between H-1 and c, and 9.8 ± 6.4 percent crossing over between H-3 and A, both cases in heterozygous females. These values may be high. Evidence is presented that F1 hybrids, with the tumor donor as one parent, are less compatible with tumor grafts than the native strain. With one exception, the resistance shown by the hybrid was slight. It was not increased by immunization. The extent to which the synthesized IR lines and their inbred mates approach the true coisogenic state is discussed. Table 15 presents a summary of the current state of our information in regard to the H-2 locus.
Rubella (German Measles)
Authors: Conrad Wesselhoeft
Journal: New England Journal of Medicine (1947)

AT THE annual meeting of the Ophthalmological Society of Australia in 1941 Gregg1 reported a series of congenital cataracts in 78 cases following attacks of rubella in the early months of pregnancy. Since then, numerous studies have been made regarding the prenatal influence of this disease with results indicating that the fetus may suffer a variety of defects leading to serious congenital malformations or that the fetus may be destroyed in utero with consequent miscarriage or stillbirth. Thus it is that a disease hitherto considered to be of little consequence and to require only differentiation from other exanthems has become . . .
Quality Indicators for Physical and Behavioral Health Care Integration
Authors: Matthew L. Goldman, Brigitta Spaeth-Rublee, Harold Alan Pincus
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal